Swiss Biotech Association
Late-Stage Biotech – Creating Value Through Business Development
Experienced dealmakers discuss how to create value through business development in an adverse financing environment.
Dr. Jullian Jones is CBO at Monte Rosa, a clinical-stage company developing molecular glue degraders. At Eli Lilly, she previously worked on the $8 billion acquisition of Loxo Oncology.
Dr. Corinne Savill is CBO at Cullinan Oncology, a clinical-stage cancer therapeutics firm. She previously led Business Development and Licensing at Novartis Pharma.
Dr. Jens Hennecke is CBO of Sotio Biotech, a clinical-stage immunotherapy company. He previously worked at Micromet on their $1.2 billion acquisition by Amgen.
Chandra P. Leo, Investment Advisor, HBM Partners
Jullian Jones, Chief Business Officer, Monte Rosa Therapeutics
Corinne Savill, Chief Business Officer, Cullinan Oncology
Jens Hennecke, Chief Business Officer, Sotio Biotech